These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 24326562)

  • 1. Hepatitis C treatment and alopecia totalis.
    Goh C
    J Investig Dermatol Symp Proc; 2013 Dec; 16(1):S59-60. PubMed ID: 24326562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin.
    Demirturk N; Aykin N; Demirdal T; Cevik F
    Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483
    [No Abstract]   [Full Text] [Related]  

  • 3. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection.
    Kartal ED; Alpat SN; Ozgunes I; Usluer G
    Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):817-20. PubMed ID: 17700271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients.
    Zeuzem S
    J Hepatol; 2008 Aug; 49(2):157-9. PubMed ID: 18554745
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful treatment after short course of telaprevir-based therapy in chronic hepatitis C infected patient.
    Dutilh JC; Arends JE
    Neth J Med; 2013 Sep; 71(7):391-2. PubMed ID: 24038569
    [No Abstract]   [Full Text] [Related]  

  • 6. Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report.
    Gamal N; Brodosi L; Misciali C; Patrizi A; Vukatana G; Malavolta N; Bernardi M; Andreone P
    Ann Hepatol; 2014; 13(2):293-6. PubMed ID: 24558223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alopecia universalis as a side effect of pegylated interferon α-ribavirin combination therapy for hepatitis C: a rare case report.
    Verma P; Dayal S; Jain VK; Amrani A
    J Chemother; 2017 Dec; 29(6):380-382. PubMed ID: 27741937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Early interruption of triple therapy with telaprevir in chronic hepatitis C due to severe adverse effects does not necessarily lead to treatment failure].
    Virolés Torrent S; López Nuñez C; Hombrados Verde M; Figa Francesch M; Ferri Iglesias MJ; Louvriex Freire R; Acero Fernández D
    Gastroenterol Hepatol; 2015 Feb; 38(2):78-81. PubMed ID: 24948444
    [No Abstract]   [Full Text] [Related]  

  • 9. Vitiligo improvement in a hepatitis C patient after treatment with PEG-interferon alpha-2a and ribavirin: a case report.
    Taffaro M; Pyrsopoulos N; Cedron H; Cacayorin E; Weppler D; Moon J; Nishida S; Levi D; Kato T; Selvaggi G; Tzakis A; Schiff E
    Dig Dis Sci; 2007 Dec; 52(12):3435-7. PubMed ID: 17431776
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of re-treatment by peginterferon alpha-2a and ribavirin in a child with hepatitis C.
    Nishimata S; Tsutsumi N; Suzuki S; Nagao R; Kashiwagi Y; Kawashima H
    J Infect Chemother; 2014 Jul; 20(7):443-5. PubMed ID: 24793175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic hepatitis C successfully treated with telaprevir, pegylated interferon and ribavirin in severe aplastic anemia.
    Balkan II; Bozcan S; Yemisen M; Kutlubay Z; Ozaras R
    Ann Hepatol; 2014; 13(6):843-4. PubMed ID: 25332274
    [No Abstract]   [Full Text] [Related]  

  • 12. Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C.
    Villa E; Cammà C; Di Leo A; Karampatou A; Enea M; Gitto S; Bernabucci V; Losi L; De Maria N; Lei B; Ferrari A; Vukotic R; Vignoli P; Rendina M; Francavilla A
    J Viral Hepat; 2012 Sep; 19(9):640-9. PubMed ID: 22863268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A step forward in therapy for hepatitis C.
    Hoofnagle JH
    N Engl J Med; 2009 Apr; 360(18):1899-901. PubMed ID: 19403908
    [No Abstract]   [Full Text] [Related]  

  • 15. [Telaprevir, PEG-IFNα-2b and ribavirin combination therapy for difficult to treat patients with genotype 2 chronic hepatitis C].
    Nishimura T
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():193-8. PubMed ID: 26845929
    [No Abstract]   [Full Text] [Related]  

  • 16. [PEG-interferons: significance for the treatment of viral hepatitis B and C].
    Wedemeyer H; Cornberg M; Manns MP
    Dtsch Med Wochenschr; 2001 Jun; 126 Suppl 1():S68-75. PubMed ID: 11450618
    [No Abstract]   [Full Text] [Related]  

  • 17. New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye.
    Dusheiko G; Wedemeyer H
    Gut; 2012 Dec; 61(12):1647-52. PubMed ID: 22936671
    [No Abstract]   [Full Text] [Related]  

  • 18. Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI).
    Couzigou P; Pérusat S; Bourlière M; Trimoulet P; Poynard T; Leroy V; Marcellin P; Foucher J; Bronowicki JP; Chêne G;
    J Gastroenterol Hepatol; 2013 Feb; 28(2):329-34. PubMed ID: 23190183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
    Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P
    Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADVANCE study begins enrollment.
    AIDS Patient Care STDS; 2008 Apr; 22(4):345. PubMed ID: 18422463
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.